Logo Image
In Brief
Spotlight

Lilly partners with Haya for lncRNA obesity target deal worth $1bn

Haya could secure up to $1bn after hitting preclinical, clinical, and commercial milestones with drugs that emerge from this deal.

Latest news

ESC 2024: Insights into RNA as therapeutic target and tool

On the last day of the European Society of Cardiology (ESC) 2024 Congress (2 September), a panel discussed the therapeutic potential with non-coding RNAs in cardiovascular disorders.

eGenesis scoops $191m for genetically modified pig kidney transplant trial

eGenesis conducted the first-in-human porcine kidney transplant earlier this year, though the patient died two months later.

Moderna mpox mRNA vaccine shows early promise in monkey study

Moderna is currently running a Phase I/II trial of the mRNA mpox vaccine mRNA-1769 in healthy participants.

ESC 2024: CATHEDRAL-HF trial results have the potential to reduce polypharmacy

A large proportion of chronic heart failure (HF) patients are taking suboptimal doses of relevant medications.

IN8bio cuts staff and pipeline to focus on AML cell therapy

The company has reduced its headcount by about 49% and suspended enrolment in a Phase II glioblastoma trial.

Evotec partners X-Chem for tech-enabled drug discovery

X-Chem's DEL technology allows for the simultaneous screening of billions of DNA-tagged compounds.

ESC 2024: New PACMAN-AMI trial analysis sheds insights on Praluent efficacy

The subanalyses recontextualised data from the PACMAN-AMI trial on the therapeutic role of Praluent (alirocumab) in coronary heart disease.